Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott's Phase III trial of Humira (adalimumab) met primary endpoint of clinical remission in adult patients who are suffering from moderate to severe ulcerative colitis (UC).
Subscribe to our email newsletter
The study has evaluated 494 adult patients with UC who had not responded well to conventional therapy, such as corticosteroids and/or immunosuppressants.
In the trial, 16.5% of the patients achieved clinical remission compared to 9.3% on placebo at week 8.
At week 52, 17.3% achieved clinical remission compared to 8.5% on placebo. These results were statistically significant compared to placebo.
Abbott Global Pharmaceutical Clinical Development vice president Eugene Sun said they are encouraged by these study results with Humira and the potential they may have for patients.